real-world outcomes following dose reduction of first-line ibrutinib in patients with wm
Published 7 months ago • 146 plays • Length 2:22Download video MP4
Download video MP3
Similar videos
-
2:09
real-world incidence of ibrutinib-related cardiotoxicity in cll: insights from the lls registry
-
2:18
analysis of real-world outcomes in patients with b-all receiving tisagenlecleucel
-
1:43
real-world outcomes of teclistamab for r/r multiple myeloma
-
7:09
the role of real-world evidence in the evaluation of new drugs
-
8:15
妹妹最後一次看中醫！壞消息讓她哭了！需要離開台灣？
-
14:38
pharma in 2032: the case for real-world evidence
-
54:02
leveraging real world evidence for regulatory use
-
1:59
real-world outcomes of ide-cel in heavily pre-treated r/r mm
-
1:30
results of the ruxopeg trial: combining ruxolitinib and interferon in patients with myelofibrosis
-
2:43
collecting real world data from novel treatments
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
1:25
preliminary results from a phase ib trial of as-1763, a novel non-covalent btki, in cll/mcl
-
1:45
the real-world outcomes of patients with cll who discontinue btki therapy
-
1:30
outcomes in rrmm treated with ird in the real world
-
1:50
real-world outcomes of teclistamab treatment in r/r multiple myeloma
-
2:00
real-world bortezomib prescribing patterns and outcomes in ndmm
-
6:09
brexu-cel in adults with r/r b-all: a real-world outcomes collaboration
-
1:44
real-world outcomes of brexu-cel for r/r b-all: evidence from the cibmtr registry
-
3:48
impressive data: zanubrutinib for waldenström’s macroglobulinemia
-
3:02
the effects of maintenance therapy on real-world outcomes for patients with ndmm
-
5:40
final results from the ukall60 trial